CN1652815A - 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 - Google Patents

针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 Download PDF

Info

Publication number
CN1652815A
CN1652815A CNA03810797XA CN03810797A CN1652815A CN 1652815 A CN1652815 A CN 1652815A CN A03810797X A CNA03810797X A CN A03810797XA CN 03810797 A CN03810797 A CN 03810797A CN 1652815 A CN1652815 A CN 1652815A
Authority
CN
China
Prior art keywords
antibody
atcc
preserving number
usa
manassas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03810797XA
Other languages
English (en)
Chinese (zh)
Inventor
三箇山俊文
王荣方
加藤慎一郎
H·切罗特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Pharma KK
La Jolla Institute for Allergy and Immunology
Original Assignee
Kirin Brewery Co Ltd
La Jolla Institute for Allergy and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd, La Jolla Institute for Allergy and Immunology filed Critical Kirin Brewery Co Ltd
Publication of CN1652815A publication Critical patent/CN1652815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
CNA03810797XA 2002-03-13 2003-03-13 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 Pending CN1652815A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36499702P 2002-03-13 2002-03-13
US60/364,997 2002-03-13

Publications (1)

Publication Number Publication Date
CN1652815A true CN1652815A (zh) 2005-08-10

Family

ID=28041999

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03810797XA Pending CN1652815A (zh) 2002-03-13 2003-03-13 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法

Country Status (9)

Country Link
US (1) US20030219442A1 (https=)
EP (1) EP1490099A4 (https=)
JP (1) JP2005519619A (https=)
KR (1) KR20040111402A (https=)
CN (1) CN1652815A (https=)
AU (1) AU2003223285A1 (https=)
CA (1) CA2478973A1 (https=)
TW (1) TW200407161A (https=)
WO (1) WO2003078600A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101881770A (zh) * 2009-05-08 2010-11-10 青岛农业大学 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法
CN102238963A (zh) * 2008-12-04 2011-11-09 英特塞尔股份公司 完全人源性流感m2特异性抗体
CN105934443A (zh) * 2014-01-27 2016-09-07 豪夫迈·罗氏有限公司 抗h7病毒抗体治疗h7n9流感
CN106715700A (zh) * 2014-01-10 2017-05-24 艾乐美生物科技有限公司 能产生比小鼠IgE量高出许多的人源化IgE的基因转殖动物
CN112961237A (zh) * 2021-03-10 2021-06-15 中国计量科学研究院 人源化IgM单克隆抗体标准物质及制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1819732A2 (en) * 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
GB0522460D0 (en) * 2005-11-03 2005-12-14 Prendergast Patrick T Composition and method for the treatment of avian influenza
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
EP2024393A2 (en) * 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
WO2008110937A2 (en) * 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
NZ585500A (en) * 2007-11-12 2012-06-29 Theraclone Sciences Inc Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
TWI473621B (zh) * 2008-11-12 2015-02-21 Theraclone Sciences Inc 供治療和診斷流感用之組成物和方法
WO2010110737A1 (en) * 2009-03-23 2010-09-30 Temasek Life Sciences Laboratory Limited Monoclonal antibody against a conserved domain of m2e polypeptide in influenza viruses
JP2012527473A (ja) * 2009-05-20 2012-11-08 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
CN106478816B (zh) * 2016-12-12 2019-08-16 青岛蔚蓝生物制品有限公司 一种抗禽流感h9n2病毒的单链抗体
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103243A (en) * 1985-05-15 2000-08-15 Biotechnology Australia Pty, Ltd Oral vaccines
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5290686A (en) * 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5686078A (en) * 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
EP0678034B1 (en) * 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
WO1994015640A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
ES2255181T3 (es) * 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antigeno inmunoprotector contra la gripe y su uso en vacunacion.
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
WO2000032626A1 (en) * 1998-11-25 2000-06-08 Regents Of The University Of Minnesota Methods of using epitope peptides of human pathogens
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102238963A (zh) * 2008-12-04 2011-11-09 英特塞尔股份公司 完全人源性流感m2特异性抗体
CN101881770A (zh) * 2009-05-08 2010-11-10 青岛农业大学 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法
CN101881770B (zh) * 2009-05-08 2013-07-10 青岛农业大学 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法
CN106715700A (zh) * 2014-01-10 2017-05-24 艾乐美生物科技有限公司 能产生比小鼠IgE量高出许多的人源化IgE的基因转殖动物
CN105934443A (zh) * 2014-01-27 2016-09-07 豪夫迈·罗氏有限公司 抗h7病毒抗体治疗h7n9流感
CN112961237A (zh) * 2021-03-10 2021-06-15 中国计量科学研究院 人源化IgM单克隆抗体标准物质及制备方法

Also Published As

Publication number Publication date
WO2003078600A2 (en) 2003-09-25
EP1490099A4 (en) 2006-02-08
AU2003223285A1 (en) 2003-09-29
US20030219442A1 (en) 2003-11-27
KR20040111402A (ko) 2004-12-31
AU2003223285A8 (en) 2003-09-29
JP2005519619A (ja) 2005-07-07
EP1490099A2 (en) 2004-12-29
WO2003078600A3 (en) 2004-07-01
TW200407161A (en) 2004-05-16
CA2478973A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
CN1652815A (zh) 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法
JP4881874B2 (ja) インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
US20050170334A1 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
CN1413220A (zh) 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法
US20130243750A1 (en) Anti-ige antibodies and methods using same
CN1829806A (zh) 产生高亲和力抗体的方法
CN1914226A (zh) SARS－CoV抗体及其使用方法
CN1407993A (zh) 基因重组抗体及其抗体片段
CN1889979A (zh) Ip－10抗体及其用途
CN1838968A (zh) 针对甲状旁腺激素(pth)之抗体和其用途
CN1551783A (zh) 治疗多发性骨髓瘤的方法
CN1642983A (zh) 抗C5aR抗体及其应用
US8003106B2 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
CN1747971A (zh) 抗Nogo A的抗体(“11C7”)及其药物用途
CN1878792A (zh) Nogo－a结合分子及其药物用途
HK1081439A (en) Human monoclonal antibodies to influenza m2 protein and methods of making and using same
CN1809591A (zh) 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体
CN1934266A (zh) 抗肌肉生长抑素抗体
CN1225478C (zh) 嵌合的抗cd25单克隆抗体、其编码序列及应用
HK1101183A (en) Identification of novel ige epitopes
WO2025184137A1 (en) Influenza antibodies and methods of use thereof
CN119101164A (zh) 特异性识别masp3的抗体及其应用
WO2022095045A1 (zh) SARS-CoV-2抗体及其应用
HK1098176A (en) Anti-myostatin antibodies
CN1926149A (zh) 新的IgE表位的鉴别

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081439

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: KIRIN MEDICINE CO., LTD.; APPLICANT

Free format text: FORMER OWNER: QILIN CO., LTD.; APPLICANT

Effective date: 20080718

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080718

Address after: Tokyo, Japan

Applicant after: Kirin Pharmaceutical Co., Ltd.

Co-applicant after: La Jolla Institute For Allergy and Immunology

Address before: Tokyo, Japan

Applicant before: Kirin Holdings

Co-applicant before: La Jolla Institute For Allergy and Immunology

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050810

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081439

Country of ref document: HK